Data / Form D filings / Lumen Bioscience, Inc.
Lumen Bioscience, Inc.: Form D filings
Lumen Bioscience, Inc., a biotechnology company in Seattle, WA, filed 5 Form D notices with the SEC between 2019 and 2025. The latest, on April 1, 2025, reports an offering of $23 million with nothing sold yet.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1441 NORTH 34TH STREET, SUITE 300, Seattle, WA, 98103
- Phone
- (206) 899-1904
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1703612
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 1, 2025 | New notice | $23,000,000 | $0 | $23,000,000 | 0 | Yet to occur | sec.gov |
| Nov 19, 2024 | New notice | $18,345,489 | $0 | $18,345,489 | 0 | Yet to occur | sec.gov |
| Sep 15, 2023 | New notice | $33,000,000 | $0 | $33,000,000 | 0 | Yet to occur | sec.gov |
| Jun 29, 2022 | New notice | $50,464,302 | $0 | $50,464,302 | 0 | Yet to occur | sec.gov |
| Nov 12, 2019 | New notice | $26,052,323 | $0 | $26,052,323 | 0 | Yet to occur | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Erik Anderson | Director | |
| Ed Schlect | Director | |
| Craig Behnke | Executive Officer | |
| John Morrow | Executive Officer | |
| Robert Carlson | Director | |
| Mark Litton | Director | |
| Marcos Milla | Director | |
| Eric Orse | Executive Officer | |
| Brian Finrow | Executive Officer, Director, Promoter | |
| James Roberts | Executive Officer, Director, Promoter |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Mar 31, 2025 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Lumen Bioscience, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.